



Invertebrate-based solutions for sustainable aquaculture

CASE STUDY: Omega 3

Webinar 06/03/2019



1. Intro

What:

Case study on opportunities derived from the capacity of invertebrates to synthesize long chain omega 3 fatty acids (n-3 LC PUFA) from scratch

What for:


Assessment from a business / entrepreneurship perspective

Index:

2. Context
3. Starting point
4. Tasks ahead
5. Network
6. Business opportunities
7. SWOT

2. Starting point

1. Aquaculture is main user of LC-PUFA (>70%)
2. Aquaculture is to become the primary source of EPA/DHA for humans
 - necessary ingredient in diets
 - fish trimmings/discards = efficiency, not new sources (limited)
 - other wild sources (e.g. krill)= harvesting, not producing (SDGs)
 - land plants alternatives (n-6 Vs n-3 PUFA) require GMOs (from algae)
 - algae: cost (decreasing) but need removal of starch and proteins
3. Gap increasing
 - if 500mg/day (x 365 days x 7b people...)
then 0.5-1 10^6 t/y
 - health issues for people and farmed fish
 - other markets (farming)
4. Industrial sustainability:
efforts by large companies and investors



2. Starting point

ResearchGate

Search for publications, researchers, or questions



or

Discover by subject area

See all ›
7 Citations

See all ›
40 References

 Download citation

Genes for de novo biosynthesis of omega-3 polyunsaturated fatty acids are widespread in animals

Ad

Article (PDF Available) in [Science Advances](#) 4(5):eaar6849 · May 2018 with 294 Reads

DOI: 10.1126/sciadv.aar6849

 Cite this publication



Naoki Kabeya

ORCID iD 23.76 · The University of Tokyo



Miguel M Fonseca

ORCID iD 22.19 · University of Porto



David E K Ferrier

ORCID iD 39.54 · University of St Andrews

+ 5



Juan Carlos Navarro

ORCID iD 37.87 · Spanish National Research Council



3. Tasks ahead



- Now** 1. Get funding **(ongoing)**
- Next** 1. Better map capacity across invertebrate phyla **2-3 years**
2. Choose suitable invertebrates for industrial production
3. Assess gene expression for n-3 LC-PUFA synthesis (influential variables)
4. Develop optimal growing conditions to enhance controlled production (viability)
5. Advance in domestication and enhancement (efficiency)
- Then** 1. Assess potential markets: e.g. aquafeeds, pharma (capsules) **1-2 years**
2. Assess market expectations: product specifications, cost, volumes
3. Develop product and marketing strategy
4. Carry out trials and develop processing technology
5. Quantify financial needs: infrastructure, equipment, staff, external services.
- Finally** 1. Explore business models **asap**
2. Choose between venturing or transferring (different modalities)



4. International network (EXAMPLE ONLY, FICTIONAL)



Funding mechanism (pub/priv)
RDI funding

Research institute (pub)
genomics

Aquaculture farm (priv)
polychaete production and enhancement

+

Research company (priv)
amphipod production and enhancement

Tech partner (priv)
Environmental control, processing and automatisisation

Feed company (priv)
Feed design and testing

+

Pharma/Biotech company (priv)
Product design and testing

Cluster (pub/priv)
market analysys and business support

New SME
Production and marketing

/

Technological park / Incubator (pub)
Transfer to SMEs



5. Business opportunities



- 1. Lower cost or sustainability edge for invertebrate production of n-3 LC PUFA (EPA/DHA)**
 - farmed detritivores Vs wild catches, algae, GMOs
- 2. Increasing efficiency and revenue by integrating systems**
 - valorisation of waste while producing high-value ingredients
- 3. Unknown potential of understanding and controlling gene expression (for Omega3 synthesis using low cost diets)**

Depending on:

- viability, real potential and efficiency
- market and resource evolution (relative costs according to source)



Strengths

- widespread capacity
- advances in genetic and productive enhancement
- edge over wild sources and algal inputs
- avoids GMOs
- funding and clients ensured
- performant and balanced consortium
- embedded in natural diet

Opportunities

- high market demand
- sustainability
- stakeholders (inc. investors) are interested
- long term competitive edge

Weaknesses

- uncertainties
- controlling metabolic expression
- time necessary for preliminary evaluation
- boom in wild harvesting (e.g. krill)
- development of plant based alternatives (e.g. GM canola)

Threats

- as research line: none (but results could disappoint)
- as business: too early to assess (production costs Vs alternative sources)
- decreasing cost of algal sources
 - now 39\$/kg (dry) down to 10\$/kg ?

Thank you.
If you have any comments or questions
please write to:

contact: Luis Lozano
Innagate to Europe SL
llg@innogateto europe.eu

info@invertebrateit.eu
www.invertebrateit.eu